LONDON–(BUSINESS WIRE)–#GlobalGonorrheaTherapeuticsMarket—Industry Boosted by the Growing Use of New Diagnostic Tests
The global gonorrhea therapeutics market size is expected to grow by USD 350.90 million during 2020-2024, progressing at a CAGR of almost 5% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of the Market Impact of COVID-19.
The rising prevalence of gonorrhea has resulted in the advent of new diagnostic tests such as nucleic acid amplification tests (NAATs). NAATs allows early diagnostic screening that helps in preventing the spread of the infection to the upper genital tract. NAATs are highly preferred over traditional cultures since they show improved sensitivity and selectivity for Neisseria gonorrhoeae at rectal and oropharyngeal sites in men. Thus, the growing use of new diagnostic tests is expected to drive the gonorrhea therapeutics market growth.
Report Highlights
- The major gonorrhea therapeutics market share came from the monotherapy segment in 2019, and it is expected to witness the fastest growth during the next five years. This is primarily because of the high potency of ceftriaxone IM or IV.
- North America was the largest gonorrhea therapeutics market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period.
- The global gonorrhea therapeutics market is fragmented. AstraZeneca Plc, Bristol-Myers Squibb Co. (Read more…), Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck & Co. Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. are some of the major market participants. To help clients improve their market position, this gonorrhea therapeutics market forecast report provides a detailed analysis of the market leaders.
- As the business impact of COVID-19 spreads, the global gonorrhea therapeutics market 2020-2024 is expected to have neutral & at par growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.
Read the full report here: www.technavio.com/report/gonorrhea-therapeutics-market-industry-analysis?
Rise in Government Initiatives to Combat Antibiotic Resistance will be a Key Market Trend
The rise in government initiatives to combat antibiotic resistance is one of the key trends driving the growth of the market. Many countries are taking initiatives to combat antibiotic resistance. For instance, the US government released a plan, ‘Combat Antibiotic-Resistant Bacteria’ (CARB), which helps in the prevention, detection, and control of antibiotic resistance. As a result, this control of antibiotic resistance in gonorrheal infection will increase patient adherence towards antibiotic therapy.
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Gonorrhea Therapeutics Market 2020-2024 : Key Highlights
- CAGR of the market during the forecast period 2020-2024
- Detailed information on factors that will assist gonorrhea therapeutics market growth during the next five years
- Estimation of the gonorrhea therapeutics market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the gonorrhea therapeutics market
- Analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of gonorrhea therapeutics market vendors
Register for a free trial today and gain instant access to 17,000+ market research reports
Technavio’s SUBSCRIPTION platform
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/